Shandong Cancer Hospital and Institute: Phase 3 study in Diffuse Intrinsic Pontine Gliomas (DIPG) (142 participants)
Shandong Cancer Hospital and Institute: Phase 3 study in Diffuse Intrinsic Pontine Gliomas (DIPG) (142 participants). Its enrollment of 142 is above the median of 80 (69th percentile). Dated 27 days ago, it is in the active follow-up window. Score 55/100. As of 2026-11-05, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 142 · 69th percentile of 9,177 ClinicalTrialStartPulse records · 1.8x the median
Free preview: all 14 published fields of this record are shown below. Locked: 499 related ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | Shandong Cancer Hospital and Institute |
| Sponsor type | Academic and hospital |
| Study | IMPT Versus IMRT for Diffuse Intrinsic Pontine Glioma |
| NCT ID | NCT07869524 |
| Phase | Phase 3 |
| Status | not yet recruiting |
| Conditions | Diffuse Intrinsic Pontine Gliomas (DIPG) |
| Intervention types | radiation |
| Target enrollment | 142 |
| Site countries | China |
| Posted | 2026-10-09 |
| Planned start | 2026-12-01 |
| Event | Newly registered study |
| Event date | 2026-10-09 |
| enrollment percentile | 69th of 9,177 (median 80, 1.8x median) |
| Peer records CSV (500 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Shandong Cancer Hospital and Institute
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Unlock Shandong Cancer Hospital and Institute + 500 peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-10-09
- Data refreshed: 2026-11-05
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (NONUS first): University of Oxford · DejthidaNathaphong · Eye & ENT Hospital of Fudan University · Shanghai First Maternal and Infant Health Hospital affiliate · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Thu, 05 Nov 2026 08:46:16 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: Shandong Cancer Hospital and Institute and 6,823 NONUS peers
- NONUS ClinicalTrialStartPulse records like this one: 6,823
- Shandong Cancer Hospital and Institute's enrollment: 69th percentile of 9,177 records
- Timing: Medium: dated in the last 30 days
- Estimated pipeline if you contact every NONUS peer: $1,364,600 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
55 / 100 Score
- Phase 3: multi-site, larger budget.
- 142 participants planned.
- Not yet recruiting: vendors still being chosen.
What is the ClinicalTrialStartPulse record for Shandong Cancer Hospital and Institute?
Shandong Cancer Hospital and Institute registered a Phase 3 study (NCT07869524) in Diffuse Intrinsic Pontine Gliomas (DIPG) targeting 142 participants, posted 2026-10-09.
How does Shandong Cancer Hospital and Institute compare to other ClinicalTrialStartPulse records?
Its enrollment of 142 sits in the upper half (69th percentile) of 9,177 records; the median is 80. It is 27 days old, still within a typical 45-day follow-up window.
Shandong Cancer Hospital and Institute vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| Shandong Cancer Hospital and Institute | NONUS | 142 | 69th | 2026-10-09 |
| Fujian Shengdi Pharmaceutical Co., Ltd. | NONUS | 144 | 69th | 2026-11-04 |
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NONUS | 420 | 88th | 2026-11-04 |
| Innovent Biologics (Suzhou) Co. Ltd. | NONUS | 500 | 90th | 2026-11-04 |
Related records
- NervGen Pharma
- Biogen
- Teva Branded Pharmaceutical Products R&D LLC
- Eli Lilly and Company
- Arcutis Biotherapeutics, Inc.
- Innovent Biologics (Suzhou) Co. Ltd.
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Stemline Therapeutics, Inc.
- AstraZeneca
- Teva Branded Pharmaceutical Products R&D LLC
- Genmab
ClinicalTrialStartPulse: Phase 3 ClinicalTrialStartPulse: Outside the US only
How to monitor Shandong Cancer Hospital and Institute and peer phase 3 records
Get new ClinicalTrialStartPulse records like Shandong Cancer Hospital and Institute by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.